The International Testing Agency (ITA), on behalf of the Olympic Council of Asia (OCA), reports that Kazakh rugby player Diana Andriyenko has accepted the consequences for her anti-doping rule violation (ADRV) under the OCA anti-doping rules
The ITA reports that a sample collected from rugby player Diana Andriyenko during an in-competition anti-doping control on 1 October 2026 in Nagoya, Japan, returned an adverse analytical finding[1] for sibutramine metabolites.
Sibutramine is prohibited under the WADA Prohibited List as S6.B ‘Specified Stimulants’. It is a synthetic stimulant drug that suppresses appetite and alters neurotransmitter levels, leading to increased energy expenditure and weight loss effects. Sibutramine is a specified substance prohibited in-competition.
The athlete accepted the consequences of her ADRV under the OCA anti-doping rules (OCA ADR), namely the finding of the ADRV and the disqualification of all her individual results obtained at the 20th Asian Games Aichi-Nagoya 2026, including her results in the Kazakhstan Rugby Sevens competition on 1, 2 and 3 October 2026. In accordance with the OCA ADR, the results of the Kazakhstan Women’s Rugby Sevens team are not to be disqualified.
The matter is considered as concluded from the perspective of the OCA and has been referred to World Rugby for a determination of further consequences under the World Rugby anti-doping rules.
There will be no further comments on this case.